We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Genetic "Hotspots” Tailor Therapies for Bowel Cancer Treatment

By LabMedica International staff writers
Posted on 22 Feb 2010
A new study has identified the repetition frequency of new genetic "hotspots,” which could help doctors offer personalized therapies for bowel cancer patients.

Researchers at the University of Dundee (United Kingdom) carried out a genetic analysis on 106 bowel cancer tumor samples to search for the frequency of known faults in a key gene called K-Ras--an important protein which acts as an "on-off switch” in cells to control growth--since it is already known that in some bowel cancers the K-Ras gene is faulty, leaving the switch permanently "on.” The researchers screened the colorectal tumors for additional K-Ras mutation phenotypes and Ras guanine triphosphate (GTP)-ase activating assays and gene and pathway changes induced by individual K-Ras mutants. More...


The researchers found that besides the current K-Ras "hotspots” in codons 12, 13, and 61, four additional K-Ras mutations (Leu19Phe, Lys117Asn, Ala146Thr, and Arg164Gln) were identified, most commonly at codon 146. The researchers additionally identified a new K-Ras gene amplification event, present in approximately 2% of tumors. According to the researchers, the study suggests that as many as 33% of bowel cancer patients have a K-Ras fault. As a result, they recommend future mutation screening to facilitate optimal patient selection for treatment with Epidermal Growth Factor Receptor (EGFR)-targeted therapies should therefore be extended to codon 146, and in addition should consider the unique molecular signatures associated with individual K-Ras mutations. The study was published early online on February 9, 2010, in the British Journal of Cancer.

"These results highlight additional gene faults which potentially could be tested for in bowel cancer patients to determine which people will respond best to which drugs,” said lead author Gillian Smith, Ph.D. "The next stage is to develop effective tests to screen for these mutation 'hotspots' to help doctors to plan the most effective treatment strategies for bowel cancer patients - and this will encourage scientists to also focus their efforts on finding new treatments for patients with faulty K-Ras genes to give them more options.”

Targeted therapies are drugs that are designed to treat cancer cells while minimizing damage to normal, healthy cells. The drugs interfere with specific pathways involved in cancer cell growth or survival, such as blocking growth signals and reducing the blood supply to cancer cells; others stimulate the immune system to recognize and attack the cancer cell. The two types of targeted therapy that are currently being used for colorectal cancer are EGFR inhibitors--such as panitumumab, a monoclonal antibody that binds to and blocks EGFR--and antiangiogenic drugs.

Related Links:

University of Dundee



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.